CAC
ASBPW

Cowen and Company’s Aspire Biopharma Warrant ASBPW Stock Holding History

Cowen and Company’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,700
Closed -$1.21K – 427
2024
Q3 		$1.21K Buy
+28,700
New +$1.37K ﹤0.01% 595

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Cowen and Company's ASBPW Position: Q4 2024 in Review

Cowen and Company sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2024, closing a stake of 28,700 shares — an estimated $1.21K sold.

Cowen and Company first reported a position in ASBPW in Q3 2024 and held it in 1 quarter. The position peaked at $1.21K in Q3 2024. 26 funds tracked by Wall St. Rank hold ASBPW as of Q4 2024.

  • Cowen and Company reported no remaining Aspire Biopharma Warrant position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 28,700 Aspire Biopharma Warrant shares in Q4 2024, an estimated $1.21K.
  • Cowen and Company first reported a position in Aspire Biopharma Warrant in Q3 2024 and held it in 1 quarter.
  • Cowen and Company's Aspire Biopharma Warrant position peaked at $1.21K in Q3 2024.
  • 26 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.